Many clients report feeling more energized and clearer-headed even before treatment concludes
L-arginine-NO system participates in the analgesic effect of flunixin meglumine in the rat
However, some secondary measures of nerve impairment did improve, especially in participants with higher cardiovascular risk and moderate BMI.7 Shorter-term trials have shown that 600mg/day of oral racemic ALA reduced neuropathy symptoms like burning, tingling, and numbness in as little as 35 weeks.4 20 A 2010 meta-analysis concluded that oral ALA can improve symptoms of diabetic neuropathy, but noted variability in effect sizes across trials and better results with intravenous administration.1 Despite promising results from some trials, a recent systematic review evaluating eight randomized controlled trials indicates that findings on ALA's effectiveness in treating diabetic neuropathy symptoms are inconsistent.23 While ALA proved safe and tolerable across these studies, the review concluded that definitive evidence supporting significant benefits is limited

Sulphonylureas (e.g., gliclazide, glimepiride): These medications stimulate insulin release and carry an inherent hypoglycaemia risk
Bonus: Avoid tight clothing : Although this has less to do with how you eat , its still important
CJC-1295 No DAC Dosage Chart The dosage breakdown below is based on the 10g/kg used by Khoram et al